Second and Third-Line Antiretroviral Regimens
As South Africa continues its rapid expansion of access to first-line antiretroviral therapy (ART), more patients will need to be switched to second-line therapy as these first-line regimens fail. However, with little experience with second-line treatments in resource-limited settings, it is not clear how well patients will do on these medications if their first regimen fails. As the cost of second-line medications is much higher than first-line, it is critical to evaluate whether these medications can be delivered effectively as part of a large-scale public health response to HIV. To date there have been only a limited number of such evaluations, as they require large databases to conduct a robust evaluation. HE2RO has developed a body of work evaluating the need for second-line ART as well as rates of failure on second-line and the need for third-treatment.
Publications
The following publications emanate from this project:
-
Adverse drug reactions among patients initiating second-line antiretroviral therapy in South Africa
-
Assessing the association between changing NRTIs when initiating second-line ART and treatment outcomes
-
Predictors of switch to and early outcomes on third-line antiretroviral therapy at a large public-sector clinic in Johannesburg, South Africa
-
Social and behavioral factors associated with failing second-line ART: results from a cohort study at the Themba Lethu Clinic, Johannesburg, South Africa
-
Treatment outcomes of over 1000 patients on second-line, protease inhibitor-based antiretroviral therapy from four public-sector HIV treatment facilities across Johannesburg, South Africa
-
Changes in second-line regimen durability and continuity of care in relation to national ART guideline changes in South Africa
-
Rates and Predictors of Failure of First-line Antiretroviral Therapy and Switch to Second-line ART in South Africa
-
Low rates of nucleoside reverse transcriptase inhibitor resistance in a well monitored cohort in South Africa on antiretroviral therapy
-
High rates of survival, immune reconstitution, and virologic suppression on second-line antiretroviral therapy in South Africa
-
The high cost of second line antiretroviral therapy for HIV/AIDS in South Africa
HE2RO staff involved
Dr. Lawrence Long Dr. Matthew Fox Dr. Denise Evans Dr Dorina Onoya Dr Gesine Meyer-Rath Dr Mhairi Maskew Dr. Ribka Berhanu Dr. Kate ShearerStay up to date
Receive newsletters and keep up to date with developments at HE2RO.